BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

Purpose: The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early prognosis index at 3 months in the patients with newly diagnosed CML-CP, especially for the patients with BCR-ABL1(IS) >10%....

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Zhimei, Jia, Xiting, Zi, Jie, Song, Huihui, Wang, Shujun, McGrath, Mary, Zhao, Lidong, Song, Chunhua, Ge, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052929/
https://www.ncbi.nlm.nih.gov/pubmed/32127950
http://dx.doi.org/10.7150/jca.38752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052929/
https://www.ncbi.nlm.nih.gov/pubmed/32127950
http://dx.doi.org/10.7150/jca.38752

Ejemplares similares